Results 1 to 10 of about 697,104 (329)

Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax [PDF]

Frontiers in Immunology, 2018
Anthrax is an era old deadly disease against which there are only two currently available licensed vaccines named anthrax vaccine adsorbed and precipitated (AVP).
Anshu Malik, Manish Gupta, Rajesh Mani, Himanshu Gogoi, Rakesh Bhatnagar   +4 more
doaj   +5 more sources

PaR1 secreted by the type IX secretion system is a protective antigen of Riemerella anatipestifer [PDF]

Frontiers in Microbiology, 2023
Riemerella anatipestifer mainly infects domestic ducks, geese, turkeys, and other birds, and causes considerable economic losses to the global duck industry. Previous studies have shown that concentrated cell-free culture filtrates of R.
Jialing Wang, Yan Chen, Xiaohua He, Xiaoli Du, Yongheng Gao, Xinggen Shan, Zhiqun Hu, Qinghai Hu   +7 more
doaj   +2 more sources

Recombinant full-length Bacillus Anthracis protective antigen and its 63 kDa form elicits protective response in formulation with addavax [PDF]

Frontiers in Immunology, 2023
IntroductionBacillus anthracis is the causative agent for the lethal disease anthrax, primarily affecting animals and humans in close contact with an infected host. The pathogenicity of B. anthracis is attributed to the secreted exotoxins and their outer
Shikhar Sharma, Shikhar Sharma, Vanndita Bahl, Gaurav Srivastava, Risha Shamim, Rakesh Bhatnagar, Deepak Gaur   +6 more
doaj   +2 more sources

Impact of HLA Polymorphism on the Immune Response to Bacillus Anthracis Protective Antigen in Vaccination versus Natural Infection [PDF]

Vaccines, 2022
The causative agent of anthrax, Bacillus anthracis, evades the host immune response and establishes infection through the production of binary exotoxins composed of Protective Antigen (PA) and one of two subunits, lethal factor (LF) or edema factor (EF).
Stephanie Ascough, Rebecca J. Ingram, Karen K. Y. Chu, Stephen J. Moore, Theresa Gallagher, Hugh Dyson, Mehmet Doganay, Gökhan Metan, Yusuf Ozkul, Les Baillie, E. Diane Williamson, John H. Robinson, Bernard Maillere, Rosemary J. Boyton, Daniel M. Altmann   +14 more
doaj   +2 more sources

Two approaches for the stabilization of Bacillus anthracis recombinant protective antigen [PDF]

Human Vaccines & Immunotherapeutics, 2021
Anthrax is a zoonotic disease caused by the gram-positive spore-forming bacteria Bacillus anthracis. There is a need for safe, highly effective, long-term storage vaccine formulations for mass vaccination. However, the development of new subunit vaccines
Ekaterina M. Ryabchevskaya, Ekaterina A. Evtushenko, Dmitry L. Granovskiy, Peter A. Ivanov, Joseph G. Atabekov, Olga A. Kondakova, Nikolai A. Nikitin, Olga V. Karpova   +7 more
doaj   +2 more sources

Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine [PDF]

Human Vaccines & Immunotherapeutics, 2020
Polysaccharides isolated from natural plants may represent a novel source of vaccine adjuvants. In this research, we focused on a natural plant polysaccharide, PCP-I, which is derived from Poria cocos, a Chinese traditional herbal medicine.
Kun Liu, Ying Yin, Jun Zhang, Xiaodong Zai, Ruihua Li, Hao Ma, Junjie Xu, Junjie Shan, Wei Chen   +8 more
doaj   +2 more sources

Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate. [PDF]

NPJ Vaccines
Desalegn G, Tamilselvi CS, Lemme-Dumit JM, Heine SJ, Dunn D, Ndungo E, Kapoor N, Oaks EV, Fairman J, Pasetti MF.   +9 more
europepmc   +3 more sources

Co-Administration of Aluminium Hydroxide Nanoparticles and Protective Antigen Domain 4 Encapsulated Non-Ionic Surfactant Vesicles Show Enhanced Immune Response and Superior Protection against Anthrax. [PDF]

Vaccines (Basel), 2020
Gogoi H, Mani R, Malik A, Sehrawat P, Bhatnagar R.   +4 more
europepmc   +3 more sources

Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa. [PDF]

, 2013
BACKGROUND: Tuberculosis (TB) remains a global health threat with 9 million new cases and 1.4 million deaths per year. In order to develop a protective vaccine, we need to define the antigens expressed by Mycobacterium tuberculosis (Mtb), which are ...
AA Odutola, Adane Mihret, Amelia C. Crampin, Andre G. Loxton, BC de Jong, Bonnie A. Thiel, CS Lindestam Arlehamn, Desta Kassa, EM Leyten, Gerhard Walzl, GF Black, GF Black, Gillian F. Black, Harriet Mayanja-Kizza, Hazel M. Dockrell, I Comas, Jayne S. Sutherland, JD Ernst, JS Sutherland, Kees Franken, L Goldsack, Lyn R. Ambrose, Maeve K. Lalor, Marie P. Gomez, Martin Ota, MD Tameris, Michel R. Klein, N Caccamo, N Inokuchi, NN Chegou, Novel N. Chegou, Pere-Joan Cardona, Rawleigh Howe, RL Leistikow, S Commandeur, SH Macdonald, Shreemanta K. Parida, Simon Donkor, Stefan H. E. Kaufmann, TH Ottenhoff, TH Ottenhoff, TH Ottenhoff, Tom H. M. Ottenhoff, W Santema, W. Henry Boom, Willem Hanekom, WY Phong   +46 more
core   +17 more sources

DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8+ T Cell Responses, Enabling Faster Resolution of Influenza Disease [PDF]

, 2016
Current influenza vaccines are effective but imperfect, failing to cover against emerging strains of virus and requiring seasonal administration to protect against new strains. A key step to improving influenza vaccines is to improve our understanding of
Bogen, B, Brunsvik Frediksen, A, Grodeland, G, Kinnear, E, Lambert, L, Lindberg, MM, Mcdonald, JU, Stubsrud, E, Tregoning, JS   +8 more
core   +10 more sources